Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pediatr Blood Cancer. 2024 Aug;71(8):e31065. doi: 10.1002/pbc.31065. Epub 2024 May 9.
The addition of rituximab to standard regimens for primary mediastinal large B-cell lymphoma (PMBCL) has significantly improved overall survival. However, the optimal management of isolated central nervous system (CNS) relapse and role of CNS prophylaxis remains undefined. We present cases of two adolescents with PMBCL who developed isolated CNS relapses. While isolated CNS relapse may be managed with high-dose chemotherapy and autologous stem cell transplant with or without CNS radiotherapy, review of these cases and the literature highlight the need for further work to define risk factors for CNS relapse, and identify patients who may benefit from CNS prophylaxis.
利妥昔单抗联合标准方案治疗原发性纵隔大 B 细胞淋巴瘤(PMBCL)可显著提高总生存率。然而,孤立性中枢神经系统(CNS)复发的最佳治疗方法和 CNS 预防的作用仍未确定。我们报告了 2 例青少年 PMBCL 患者发生孤立性 CNS 复发的病例。虽然孤立性 CNS 复发可以通过大剂量化疗和自体干细胞移植联合或不联合 CNS 放疗来治疗,但对这些病例和文献的回顾强调需要进一步研究来确定 CNS 复发的危险因素,并确定可能从 CNS 预防中获益的患者。